223 related articles for article (PubMed ID: 19108889)
1. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.
Lancet JE; Baer MR; Duran GE; List AF; Fielding R; Marcelletti JF; Multani PS; Sikic BI
Leuk Res; 2009 Aug; 33(8):1055-61. PubMed ID: 19108889
[TBL] [Abstract][Full Text] [Related]
2. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine.
Gerrard G; Payne E; Baker RJ; Jones DT; Potter M; Prentice HG; Ethell M; McCullough H; Burgess M; Mehta AB; Ganeshaguru K
Haematologica; 2004 Jul; 89(7):782-90. PubMed ID: 15257929
[TBL] [Abstract][Full Text] [Related]
3. Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia.
Marcelletti JF; Multani PS; Lancet JE; Baer MR; Sikic BI
Leuk Res; 2009 Jun; 33(6):769-74. PubMed ID: 18976810
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.
Rubin EH; de Alwis DP; Pouliquen I; Green L; Marder P; Lin Y; Musanti R; Grospe SL; Smith SL; Toppmeyer DL; Much J; Kane M; Chaudhary A; Jordan C; Burgess M; Slapak CA
Clin Cancer Res; 2002 Dec; 8(12):3710-7. PubMed ID: 12473580
[TBL] [Abstract][Full Text] [Related]
5. Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype.
Marcelletti JF; Sikic BI
Cancer Chemother Pharmacol; 2024 Jun; 93(6):595-604. PubMed ID: 38407601
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979).
Callies S; de Alwis DP; Mehta A; Burgess M; Aarons L
Cancer Chemother Pharmacol; 2004 Jul; 54(1):39-48. PubMed ID: 15045528
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.
Lê LH; Moore MJ; Siu LL; Oza AM; MacLean M; Fisher B; Chaudhary A; de Alwis DP; Slapak C; Seymour L
Cancer Chemother Pharmacol; 2005 Aug; 56(2):154-60. PubMed ID: 15809877
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Li GY; Liu JZ; Zhang B; Wang LX; Wang CB; Chen SG
Biomed Pharmacother; 2009 Sep; 63(8):566-70. PubMed ID: 19095404
[TBL] [Abstract][Full Text] [Related]
9. Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia.
Xu WL; Shen HL; Ao ZF; Chen BA; Xia W; Gao F; Zhang YN
Leuk Res; 2006 Apr; 30(4):407-13. PubMed ID: 16219352
[TBL] [Abstract][Full Text] [Related]
10. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
11. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.
Sandler A; Gordon M; De Alwis DP; Pouliquen I; Green L; Marder P; Chaudhary A; Fife K; Battiato L; Sweeney C; Jordan C; Burgess M; Slapak CA
Clin Cancer Res; 2004 May; 10(10):3265-72. PubMed ID: 15161679
[TBL] [Abstract][Full Text] [Related]
12. A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.
Advani AS; Tiu R; Saunthararajah Y; Maciejewski J; Copelan EA; Sobecks R; Sekeres MA; Bates J; Rush ML; Tripp B; Salvado A; Noon E; Howard M; Jin T; Hsi E; Egorin MJ; Lim K; Cotta CV; Price C; Kalaycio M
Leuk Res; 2010 Dec; 34(12):1622-6. PubMed ID: 20427086
[TBL] [Abstract][Full Text] [Related]
13. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999.
Cripe LD; Uno H; Paietta EM; Litzow MR; Ketterling RP; Bennett JM; Rowe JM; Lazarus HM; Luger S; Tallman MS
Blood; 2010 Nov; 116(20):4077-85. PubMed ID: 20716770
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.
Berman E; McBride M; Lin S; Menedez-Botet C; Tong W
Leukemia; 1995 Oct; 9(10):1631-7. PubMed ID: 7564501
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance of acute leukemia and a strategy to overcome it.
Motoji T; Motomura S; Wang YH
Int J Hematol; 2000 Dec; 72(4):418-24. PubMed ID: 11197207
[TBL] [Abstract][Full Text] [Related]
16. Continuous 24-h monitoring of electrocardiogram during anthracycline-based therapy in acute leukemia.
Jakl M; Horacek JM; Jebavy L; Pudil R
Leuk Res; 2009 Aug; 33(8):e109-10. PubMed ID: 19237194
[No Abstract] [Full Text] [Related]
17. Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.
Sonneveld P; Burnett A; Vossebeld P; Ben-Am M; Rosenkranz G; Pfister C; Verhoef G; Dekker A; Ossenkoppele G; Ferrant C; Yin L; Gratwohl A; Kovacsovics T; Vellenga E; Capdeville R; Löwenberg B
Hematol J; 2000; 1(6):411-21. PubMed ID: 11920222
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.
Fracasso PM; Goldstein LJ; de Alwis DP; Rader JS; Arquette MA; Goodner SA; Wright LP; Fears CL; Gazak RJ; Andre VA; Burgess MF; Slapak CA; Schellens JH
Clin Cancer Res; 2004 Nov; 10(21):7220-8. PubMed ID: 15534095
[TBL] [Abstract][Full Text] [Related]
19. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420.
Lee EJ; George SL; Caligiuri M; Szatrowski TP; Powell BL; Lemke S; Dodge RK; Smith R; Baer M; Schiffer CA
J Clin Oncol; 1999 Sep; 17(9):2831-9. PubMed ID: 10561359
[TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500).
Petersdorf SH; Rankin C; Head DR; Terebelo HR; Willman CL; Balcerzak SP; Karnad AB; Dakhil SR; Appelbaum FR
Am J Hematol; 2007 Dec; 82(12):1056-62. PubMed ID: 17696203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
